RXRX gears up for Q4 with $25.5 million revenue view as investors eye pipeline updates and REC-4881 progress ahead of FDA talks.

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the Low Risk Penny Stocks to Buy Now. On February 27, Bank of America Securities reiterated a Hold rating on Recursion Pharmaceuticals, Inc.

Don't call Recursion Pharmaceuticals (NASDAQ: RXRX) a biotech company. Its management prefers the term "TechBio." While many have been skeptical about TechBio in the past, the reception is changing ...

Recursion Pharmaceuticals Inc RXRX shares are under pressure Wednesday after new regulatory filings showed that Nvidia Corp NVDA has fully exited its investment in the AI‑focused drug‑discovery ...

The consensus estimate for Q4 2025 revenue is $24.59 million, and the earnings are expected to come in at -$0.27 per share. The full year 2025's revenue is expected to be $61.58 million and the ...

The last time I wrote about Recursion Pharmaceuticals, Inc. (RXRX), it was in a Seeking Alpha article entitled “Recursion: Path Forward For REC-994 Remains Despite Mixed Response.” In the article, I ...

The concept of a meme stock was born about five years ago. It refers to a publicly traded company that gains substantial market value practically overnight (sometimes literally) due to significant ...

Shares of Recursion Pharmaceuticals RXRX are surging Wednesday following a robust earnings report released before the bell.

Success for just one of Recursion's phase 2 programs could enable the stock to double within five years. However, the odds of success for phase 2 candidates aren't good. Risk-averse investors should ...